Rifapentine daily + Rifapentine weekly
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis, Hiv
Trial Timeline
May 1, 2021 → Nov 1, 2021
NCT ID
NCT04551573About Rifapentine daily + Rifapentine weekly
Rifapentine daily + Rifapentine weekly is a approved stage product being developed by Gilead Sciences for Tuberculosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04551573. Target conditions include Tuberculosis, Hiv.
What happened to similar drugs?
2 of 4 similar drugs in Tuberculosis were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04551573 | Approved | Withdrawn |
Competing Products
20 competing products in Tuberculosis